



ESME Lung Cancer Publications

Health Data & Partnerships Department

Publications 2021

1. A real-world study of patients with advanced non-squamous non-small cell lung cancer with EGFR exon 20 insertion: clinical characteristics and outcomes
Chouaid C, Filleron T, Debieuvre D, Pérol M, Girard N, Dansin E, Léna H, Gervais R, Cousin S, Otto J, Schott R, Planchard D, Madroszyk A, Kaderbhai C, Dubray-Longeras P, Hirt S, Pichon E, Clément-Duchêne C, Chenuc G, Simon G, Bosquet L, Quantin X
Targeted Oncol. 2021 Nov;16(6):801-11 <https://doi.org/10.1007/s11523-021-00848-9>
2. Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort
Girard N, Pérol M, Simon G, Audigier-Valette C, Gervais R, Debieuvre D, Schott R, Quantin X, Coudert B, Lena H, carton M, Robain M, Filleron T, Chouaid C
Lung Cancer. 2021 Dec;62:119-27 <https://doi.org/10.1016/j.lungcan.2021.10.017>
3. Biomarker testing in older patients treated for an Advanced or Metastatic Non-squamous Non-Small-Cell Lung Cancer: the French ESME real-life multicenter cohort experience
Lamy T, Cabarro B, Planchard D, Quantin X, Schneider S, Bringuier M, Besse B, Girard N, Chouaid C, Filleron T, Simon G, Baldini C
Cancers. 2021 Dec;14(1):92 <https://doi.org/10.3390/cancers14010092>

4. Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany
Griesinger F, Pérol M, Girard N, Durand-Zaleski I, Zacharias S, Bosquet L, Janicke M, Quantin X, Groth A, Fleitz A, Cajella A, Patel S, Lacoïn L, Daumont MJ, Penrold JR, Carroll R, Waldenberger D, Reynaud D, Thomas M, Chouaid C.
Lung cancer. 2022 Oct;172:65-74 <https://doi.org/10.1016/j.lungcan.2022.08.001>
5. Effectiveness of nivolumab in patients with advanced non-small cell lung cancer in real-life practice in France and Germany: analysis of the ESME-AMLC and CRISP cohorts
Chouaid C, Thomas M, Debieuvre D, Durand-Zaleski I, Zacharias S, Bosquet L, Groth A, Fleitz A, Calleja A, Patel S, Lacoïn L, Dauont MJ, Penrod JR, Carroll R, Waldenberg D, Cotté FE, Audigier-Valette C, Griesinger F
Cancers. 2022 Dec;14(24):6148 <https://www.mdpi.com/2072-6694/14/24/6148#>

Publications 2023 (1/2)

6. Enrolment of older adults with advanced or metastatic non-small cell lung cancer in first-line clinical trials in the multicentre ESME cohort
Bringuier M, Carton M, Debieuvre D, Pasquier D, Pérol M, Filleron T, Léna H, Quantin X, Simon S, Baldini C
J Geriatric Oncol. 2023 Mar;14(2) <https://doi.org/10.1016/j.jgo.2022.101423>
7. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
Chouaid C, Bosquet L, Girard N, Kron A, Scheffer M, Griesinger F, Sebastian M, Trigo J, Viteri S, Rodrigues B, Rahhali N, Cabrieto J, Diels J, Perualila NJ, Schioppa CA, Sermo, J, Toueg R, Erdmann N, Mielke J, Nematian-Samani M, Martin-Fernandez C, Pfaira I, Li T, Mahadevia P, Wolf J
Adv Ther. 2023 Jan <https://link.springer.com/article/10.1007/s12325-022-02408-7>
8. Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy
Audigier-Valette C, Filleron T, Debieuvre D, Léna H, Pérol M, Chouaid C, Simon G, Quantin X, Girard N
Resp Med Res. 2023 Mar;84 <https://doi.org/10.1016/j.resmer.2023.101012>

Publications 2023 (2/2)

9. Survival outcomes of patients with metastatic Non-Small Cell Lung Cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting
Belaroussi Y, Bouteiller F, Bellera C, Pasquier D, Pérol M, Debieuvre D, Filleron T, Girard N, Schott R, Mathoulin-Pellissier S, Martin AL, Cousin S
Scientific Reports 2023 Jun;13(1):9584 <https://doi.org/10.1038/s41598-023-36623-1>
10. Reduced risk of secondary primary extra pulmonary cancer in advanced /metastatic lung cancer patients treated with immune checkpoint inhibitors
Heudel P, De Monfort A, Debieuvre D, Chouaid C, Carton M, Audigier-Valette C, Filleron T, Chabaud S, Stancu A, Quantin X, Hiret S, Bosquet L, Blay JY
Lung Cancer 2023 Jun;182:107280 <https://doi.org/10.1016/j.lungcan.2023.107280>

11. Clinical characteristics and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French Real-life ESME cohort
Thomas QD, Quantin X, Lemerrier P, Chouaid C, Schneider S, Filleron T, Remon-Masip J, Pérol M, Debieuvre D, Audigier-Valette C, Justeau G, Loeb A, Hirt S, Clément-Duchene C, Dansin E, Stancu A, Pichon E, Bosquet L, Girard N, Du Rusquec P.
ESMO Open 2024 <https://doi.org/10.1016/j.esmoop.2024.103473>
12. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database
Cabart M, Mourey L, Pasquier D, Schneider S, Lena H, Girard N, Chouaid C, Schott R, Hirt S, Debieuvre D, Quantin X, Madroszyk A, Dubray-Longeras P, Pichon E, Baranzelli A, Justeau G, Pérol M, Bosquet L, Cabarro B.
J Geriatric Oncol 2024 <https://doi.org/10.1016/j.jgo.2024.101819>
13. Optimizing treatment strategies for EGFR-mutated NSCLC treated with osimertinib: real-world outcomes and insights
Thomas QD, Girard N, Bosquet L, Cavaillon S, Filleron T, Eltaief S, Chouaid C, Lena H, Debieuvre D, Pérol M, Quantin X
Cancers 2024 <https://doi.org/10.3390/cancers16213563>

Publications 2025 (1/3)

14. Addressing challenges with Matching-Adjusted Indirect Comparisons to demonstrate the comparative effectiveness of entrectinib in metastatic ROS-1 positive Non-Small Cell Lung Cancer
Esnault C, Baschet L, Barbet V, Chenuc G, Pérol M, Thokagevistik K, Pau D, Monnereau M, Bosquet L, Filleron T
BMC Med Res Method 2025 <https://doi.org/10.1186/s12874-025-02500-w>
15. Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Lena H, Bosquet L, Girard N, Schoemaker MJ, Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M
Frontiers in oncology 2025 Feb;15 <https://doi.org/10.3389/fonc.2025.1526931>
16. Clinical Characteristics and Management of Long Survivors in Extensive Stage Small Cell Lung Cancer
Gobbini E, Diallo MH, Pasquier D, Schneider S, Chouaid C, Debieuvre D, Quantin X, Gervais R, Audigier Valette C, Justeau G, Ravoire M, Madroszyk A, Eric Pichon, Falchero L, Simoneau Y, Bylicki O, Baranzelli A, Bosquet L, Pérol M, Girard N
Lung Cancer 2025 Mar;202 <https://doi.org/10.1016/j.lungcan.2025.108499>

Publications 2025 (2/3)

17. Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study
Chouaid C, Bosquet L, Knott C, Ziming L, Schaeffer M, Lin X, Schioppa CA, Perualila NJ, Diels J, Caparros EQ, Galea F, Hulten A, Greystoke A
Lung Cancer 2025 Apr;203 <https://doi.org/10.1016/j.lungcan.2025.108548>
18. Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis
Amrane K, Cabarrou B, Justeau G, Schneider S, Quantin X, Falchero L, Bigot F, Ferrari V, Guisier F, Girard N, Lena H, Dansin E, Madroszyk A, Bizieux A, Debieuvre D, Perol M, Simmoneau Y, Bosquet L, Descourt R, Chouaid C
ESMO Open 2025 Aug;10(8) <https://doi.org/10.1016/j.esmoop.2025.105343>
19. Real-world management of unresectable stage III non-small-cell lung cancer: Impact of durvalumab consolidation therapy in French clinical practice
Chouaid C, Giraud P, Wislez M, Pichon E, Stancu A, Debieuvre D, Girard N, Prol M, Quantin X, Ano S, Grela F, Goya N, Fore M, Magne F, Pante V, Lemonnier-Videau L, Falchero L
Resp Med Res 2025 Nov <https://doi.org/10.1016/j.resmer.2025.101216>

Publications 2025 (3/3)

20. Prognostic Factors and Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Treated With Osimertinib: A Retrospective Database Study
Pérol M, Chouaid C, Macouillard P, Bosquet L, Knott C, Jose S, Edwards J, Luccarini I, Sermon J, Perualila NJ, Diels J, Penton J, Bjerrum A
ESMO Real World Data and Digital Oncology 2025 Dec
<https://doi.org/10.1016/j.esmorw.2025.100197>

21. Real-world outcomes of patients treated with ≥ 17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France
Pérol M, Audigier-Valette C, Léna H, Massiani MA, Quantin X, Santorelli M, Apert M, Spampinato A, Burke B, Chouaid C
Respir Med Res Dec 2025 <https://doi.org/10.1016/j.resmer.2025.101238>